SUR1 (short-acting) drugs for Type 2 Diabetes

2 tracked SUR1 (short-acting) drugs in the Type 2 Diabetes race. The class explanation lives on the SUR1 (short-acting) page; the full indication pipeline across every mechanism is on the Type 2 Diabetes page.

1 Phase 31 US approval withdrawn

Head-to-head evidence: Mitiglinide vs repaglinide

The roster

← all SUR1 (short-acting) drugs